News|Articles|March 21, 2025

Pharma Pulse 3/21/25: Pregnant Women Underrepresented in Clinical Trials, The Future of Value-Based Care & more

The latest news for pharma industry insiders.

Pregnant Women: An Underrepresented Group in Clinical Trials

Recent research is showing medical treatment for pregnant women often relies on clinical data from non-pregnant female patient populations.

The Future of Value-Based Care During the Trump Administration

Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company, said that achieving value-based care will need to be a multipronged approach with commercial purchasers and state Medicaid programs playing a prominent role.

The Quest for A.I. ‘Scientific Superintelligence’

An ambitious start-up embodies new optimism that artificial intelligence can turbocharge scientific discovery.

NRG Oncology and Flatiron Health announce collaboration to leverage leading technology to drive more efficient clinical trials

Flatiron Health announced a collaboration with NRG Oncology, a clinical research consortium in the National Cancer Institute’s National Clinical Trials Network comprised of over 1,300 worldwide research sites, to deploy Flatiron Clinical Pipe™ in a multicenter NRG clinical trial. Flatiron Clinical Pipe™, a cutting-edge electronic health record to electronic data capture (EDC) connector, improves efficiency and reduces time and effort of clinical study data entry.

Worldwide Clinical Trials on LinkedIn

Have you watched the Pharmaceutical Executive roundtable video series yet?

Watch Episode 1 on-demand today for key insights into the CAR T-cellh #ClinicalTrial landscape from Steve Chriscoe: https://ow.ly/iTsU50Vl1sv

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.